Deals in Depth: June/July 2009
J&J made news in July by forming a JV with Elan that will develop the latter's Alzheimer's program--including the highly touted Phase III candidate bapineuzumab--in a deal valued at $1.5bn; BMS acquired antibody technologies in its $2bn takeover of Medarex; and financing for medical device firms grew in June and July with most of the money coming from late-stage venture rounds, while biopharma fundraising went down in June but rebounded the following month thanks to a strong showing from follow-on public offerings.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.